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Abstract
Background: Glioblastoma multiforme (GBM) displays multiple amplicons and homozygous deletions that involve relevant
pathogenic genes and other genes whose role remains unknown.
Methodology: Single-nucleotide polymorphism (SNP)-arrays were used to determine the frequency of recurrent amplicons
and homozygous deletions in GBM (n= 46), and to evaluate the impact of copy number alterations (CNA) on mRNA levels of
the genes involved.
Principal Findings: Recurrent amplicons were detected for chromosomes 7 (50%), 12 (22%), 1 (11%), 4 (9%), 11 (4%), and 17
(4%), whereas homozygous deletions involved chromosomes 9p21 (52%) and 10q (22%). Most genes that displayed a high
correlation between DNA CNA and mRNA levels were coded in the amplified chromosomes. For some amplicons the impact
of DNA CNA on mRNA expression was restricted to a single gene (e.g., EGFR at 7p11.2), while for others it involved multiple
genes (e.g., 11 and 5 genes at 12q14.1–q15 and 4q12, respectively). Despite homozygous del(9p21) and del(10q23.31)
included multiple genes, association between these DNA CNA and RNA expression was restricted to the MTAP gene.
Conclusions: Overall, our results showed a high frequency of amplicons and homozygous deletions in GBM with variable
impact on the expression of the genes involved, and they contributed to the identification of other potentially relevant
genes.
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Introduction
Current knowledge about the pathogenesis of glioblastoma
multiforme (GBM) has unveiled the many genetic and molecular
alterations of its tumoral genome [1,2,3,4,5,6]. Such alterations
often result in deregulation of one or multiple oncogenic pathways,
leading to increased cell proliferation and tumor growth
[5,6,7,8,9]. Among other alterations, changes in the dosage,
sequence or structure of cancer-related genes have been recur-
rently identified, mostly in cases that carry DNA copy number
(CN) alterations of those chromosomal regions where such genes
are coded [2,3]. In recent years, several studies have highlighted
the relevance of recurrent gains of chromosome 7p, together with
10q and 9p21.3 losses, and other less frequent chromosomal
alterations [10,11,12,13]. Such numerical chromosomal changes
frequently reflect amplification/mutation of the EGFR gene (a
tyrosine kinase receptor coded at 7p11.2) and loss of the PTEN
(10q23.31) and CDKN2A (9p21.3) tumor suppressor genes
[3,13,14,15,16]. In addition, the MDM4 (1q32.1), PDGFRA
(4q12), CDK4 (12q14.1), and MDM2 (12q15) genes are also
frequently amplified in GBM, whereas inactivation of the NF1
(17q11.2), TP53 (17p13.1) and IDH1/2 (2q34/15q26.1) genes
through deletion and/or mutation is also commonly observed
[8,17,18,19,20,21].
Current availability of large-scale whole genome and gene
expression profiling (GEP)-arrays provides an invaluable tool for
detailed delineation of those genes involved in recurrent CN
alterations, and rapid assessment of their impact on the expression
levels of the involved genes. Gain-of-function mutations and both
silencing and other type of mutations, may lead to oncogene
activation and loss of function of tumor suppressor genes,
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respectively. Similarly, gene amplification and homozygous
deletion may also contribute to the development of the tumoral
phenotype. Consequently, detailed analysis of the recurrently
involved genes in amplicons and homozygous deletions is a
particularly attractive approach for identification of relevant
targeted genes. Such analysis would be particularly informative
when combined with parallel assessment of the impact of these
alterations on the levels of expression of the candidate genes, in
paired DNA and mRNA samples.
Previous array-based studies in which CN alterations are related
to GEP have contributed to the identification of cancer associated
genes relevant to GBM (e.g. MYCN, PIK3CA, CCND2, KRAS,
CHD5, CXCL12, PTER, LRRN6C, ERRFI1 and TACC3, and at the
same time they have confirmed the pathogenic role of other
known genes (e.g. EGFR) [8,22,23,24,25,26]. More recently, The
Cancer Genome Atlas (TCGA) research network [8] has further
reported occurrence of homozygous deletions of the NF1 and
PARK2 genes, and amplification of the AKT3 gene –less frequently
also of the FGFR2 and IRS2 genes–, in a series of 206 GBM. Other
candidate genes for which different mechanisms of alteration (e.g.
epigenetic silencing) have been reported in GBM, include the
RBBP5 gene (a member of the RB pathway) amplified at 1q32
[23], the CXCL12 (CXCR4 ligand involved in chemoattraction and
tumor invasion) and the HK1(a member of the hexokinase family,
known to regulate apoptotic pathways) genes [25]. Nevertheless,
high-resolution analyses of somatic CN alterations from a large
series of cancer specimens (n = 3,131) including GBM, identified
158 regions which are frequently altered across multiple cancer
types, many of which could not be explained by previously known
cancer-associated genes [27]. Despite all the above, currently there
is limited information [8,23,24,25] about the impact of DNA CN
alterations on gene mRNA expression levels in GBM..
In order to identify potentially targeted relevant genes, here we
investigated the impact of CN alterations on the expression profile
of those genes recurrently involved in amplicons and homozygous
deletions in GBM. Our results show that most genes for which a
high correlation was observed between CN alterations and gene
expression levels, are coded in those chromosomal regions for
which amplicons were detected, pointing out the potential role of
several genes coded in chromosomes 12q14(e.g. RAP1B, MDM2
andGRIP1), 4q12 (e.g. TMEM165, FIP1L1 and EXOC1), in
addition to the EGFR gene, in GBM. Conversely, the MTAP
gene coded in chromosome 9p21 was the only gene involved in
homozygous deletions whose expression levels showed a significant
correlation with the CN status.
Materials and Methods
Patients and samples
A total of 46 caucasian patients diagnosed with primary GBM
in the absence of other known genetic disorders (except for a case –
G23– who had a von Willebrandt disease) who were admitted to
the University Hospital of Coimbra (Coimbra, Portugal), were
included in this study; 21 were males and 25 females with a mean
age of 62613 years (range: 30 to 84 years) (Table 1).
In the present study, only patients with magnetic resonance
imaging (MRI), clinical evidence of disease and a histologically
confirmed diagnosis of GBM based on the World Health
Organization (WHO) criteria [28], were considered.. Other
criteria used for patient inclusion in the study were: i) availability
of enough highly-infiltrative (.75%) tumor tissue for genetic
studies, and; ii) informed consent to participate in the study given
by the patient. The study was approved by the University Hospital
of Coimbra Ethics Committee, according to the Declaration of
Helsinki protocol.
In addition to a tumor tissue specimen, paired peripheral blood
(PB) samples were also collected from each patient at diagnosis.
For every tumor sample, representative parts of fresh tumor
tissues obtained by surgical resection were immediately (,30 min)
snap-frozen in liquid nitrogen and stored at 280uC until used for
interphase fluorescence in situ hybridization (iFISH), GEP and
single-nucleotide polymorphism (SNP)-array studies. Prior to these
studies, a section cut from the tissue block was assessed by
conventional histopathological procedures, to estimate its tumor
cell contents. Specimens with $75% tumor cells, in the absence of
significant contamination by normal brain parenchyma and tumor
necrosis, were selected for further DNA and RNA extraction, as
well as for iFISH studies.
Identification of CN alterations by SNP-arrays
For the investigation of CN alterations by SNP-arrays, DNA
from frozen tumor tissue and their paired fresh PB samples was
purified using the QIAamp DNAMini Kit (Qiagen, Valencia, CA,
USA) according to the instructions of the manufacturer. DNA
yield and purity were determined with a NanoDrop-1000
spectrophotometer (Nano-Drop Technologies Inc., Wilmington,
DE, USA) and DNA integrity was evaluated by conventional
electrophoretic procedures in a 1% agarose gel. Briefly, total DNA
was digested with restriction enzymes and ligated to the
corresponding adaptors, following conventional Affymetrix proce-
dures (Affymetrix Inc., Santa Clara, CA, USA). A generic primer
was used in triplicate to amplify adaptor-ligated DNA fragments,
through a polymerase chain reaction (PCR). After hybridization
with the sample DNA, the chips were washed, labeled with
streptavidin-phycoerythrin and scanned using a GeneChip Scan-
ner 3000 (Affymetrix Inc.).
Two different SNP-array chips were used for CN analysis: 1) the
GeneChip Human Mapping 500K Array Set, which provides
information according to NCBI/hg17 assembly about .500,000
SNPs (262,264 SNPs in the Nsp array and 238,304 SNPs in the
Sty array), was applied for the study of 23 GBM, and; 2) the
Genome-Wide Human SNP Array 6.0, which contains probes for
906,600 SNPs and 945,826 non-polymorphic probes featuring a
total of .1.8 million probes (Affymetrix Inc.), was used in the
other 23 GBM (Table 1). Data about a total of 500,568 and
906,600 DNA probes was obtained in duplicate for paired tumor
and normal PB DNA samples for each array, and it was analyzed
with the Console Genotyping software (version 3.0.2; Affymetrix
Inc.). In addition, the dChip 2010 software (http //www.dchip.org;
Dana Farber Institute, Harvard, MA, USA) was used to calculate
CN values and plot them according to chromosomal localization.
Only common SNP probes between the two types of SNP-arrays
(n = 481,622) were used in the analysis. Cut-off values #1.30 and
$2.50 (arbitrary units) observed in tumor samples versus those
obtained in the paired normal PB DNA samples, were used to
establish CN losses and gains, respectively. Amplification and
homozygous deletions were defined based on CN cut-off values
obtained for DNA tumoral tissue of .5 and ,0.8 PB DNA copies
(arbitrary units), respectively.
Gene Expression Profiles (GEP)
In a subgroup of 23 tumors, total RNA was isolated from
freshly-frozen tumor tissue samples in two steps, using TRIzol
(Invitrogen Life Technologies, Carlsbad, CA, USA) and the
RNeasy Mini Kit (QIAGEN). The integrity and purity of the
extracted RNA were determined using a microfluidic electropho-
retic system (Agilent 2100 Bioanalyzer, Agilent Technologies, Palo
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:
Table 1. Clinical characteristics of GBM patients (n = 46) included in this study with information about the type of SNP-arrays used
in each case to investigate DNA CN alterations.
Case ID Age Gender
Karnofsky
Index (%)
Tumor
localization
Surgical
removal
No. of
relapses
Survival after
surgery (months)
SNP-array
analyzed
G6* 70 Female 80 Temporal ST 1 19 500K
G8* 67 Female 90 Deep ST 0 9 500K
G10* 35 Female 80 Temporal ST 0 15 500K
G12* 74 Male 70 Temporal ST 0 1 500K
G13* 39 Female 90 Frontal ST 1 21 500K
G14* 69 Female 70 Frontal ST 0 0 500K
G15* 79 Male 80 Parietal T 0 5 500K
G17* 30 Female 80 Temporal ST 3 67 500K
G23* 50 Female 80 Frontal ST 0 14 500K
G30* 71 Female 60 Temporal ST 0 9 500K
G34* 69 Male 80 Temporal ST 0 5 500K
G35* 50 Female 50 Frontal ST 0 2 500K
G37* 70 Male 80 Temporal T 1 32 500K
G39* 70 Female 70 Frontal ST 1 18 500K
G40* 45 Female 80 Frontal ST 1 15 500K
G42* 67 Male 80 Temporal ST 0 2 500K
G44* 48 Male 80 Frontal ST 0 22 500K
G45* 76 Female 60 Temporal ST 0 10 500K
G46* 62 Male 60 Frontal ST 0 3 500K
G50* 84 Male 70 Temporal ST 0 11 500K
G51* 60 Male 60 Temporal ST 0 2 500K
G52* 56 Male 90 Frontal ST 0 21 500K
G53* 74 Male 60 Frontal T 0 29 500K
G55 54 Female 80 Frontal ST 1 17 500K
G65 69 Female 60 Parietal ST 0 1 6.0
G66 60 Male 80 Occipital T 0 14 6.0
G67 68 Female 80 Parietal ST 0 35 6.0
G68 72 Male 70 Insular T 0 26 6.0
G70 56 Female 80 Occipital ST 0 21 6.0
G71 66 Female 60 Parietal ST 0 10 6.0
G72 77 Female 70 Temporal ST 0 1 6.0
G73 78 Female 60 Parietal ST 0 4 6.0
G79 71 Female 60 Occipital ST 0 6 6.0
G80 43 Male 80 Frontal T 1 18 6.0
G81 62 Female 70 Frontal ST 0 13 6.0
G82 78 Male 70 Frontal ST 0 2 6.0
G83 75 Male 70 Temporal ST 0 10 6.0
G87 45 Male 80 Temporal ST 1 16 6.0
G88 71 Male 80 Parietal ST 0 8 6.0
G89 51 Male 80 Temporal ST 0 2 6.0
G90 57 Female 60 Parietal ST 0 5 6.0
G91 73 Female 60 Occipital ST 0 13 6.0
G92 54 Female 80 Parietal T 1 15 6.0
G93# 63 Male 80 Occipital T 0 29 6.0
G94 79 Female 80 Temporal ST 0 9 6.0
G97 53 Male 80 Temporal T 0 21 6.0
Surgical removal: ST- subtotal; T- total.
*Tumors analyzed by gene expression arrays.
#Only patient that remained alive at the moment of closing the study; all other patients had died.
doi:10.1371/journal.pone.0046088.t001
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Alto, CA, USA) and GEP were analyzed with the Gene Chip
Human Genome U133 Plus 2.0 Array (Affymetrix Inc.) according
to the instructions of the manufacturer, through the one-cycle
cDNA synthesis kit and the Poly-A RNA gene chip control kit
(Affymetrix Inc), as previously reported [29]. Datafiles containing
expression values were normalized _Robust Multi-array average
expression measure (RMA)_ and analyzed using the R (version
2.7.1; http://www.r-project.org) and Bioconductor software tools
(http://www.bioconductor.org).
iFISH studies
Confirmatory iFISH studies were performed in every case
according to previously described methods [30], using a set of
commercial dual-color fluorescence labelled probes obtained from
Vysis, Inc. (Downers Grove, IL, USA) and Q-BIOgene (Carlsbad,
CA, USA), as previously described in detail [29,30]; these probes
included sequences for the TP73, ANGPTL1, EGFR, ELN, TES,
p16, ABL1, PTEN, RB1, TP53, ZNF44, GLTSCR1, and BCR genes
(Supplementary table S2). An Axioscope fluorescence microscope
equipped with a6100 oil objective (Zeiss, Go¨ttingen, Germany)
was used to count the number of hybridization spots per nuclei
($200 nuclei/slide). Only those spots with a similar size, intensity
and shape in non-overlapping nuclei, were counted; doublet
signals were considered as single spots. Briefly, gains and losses of
specific chromosomal regions were considered to occur when
$5% and $10% of the nuclei showed an increased and decreased
number of fluorescent signals (spots) with respect to normal diploid
cells, respectively. Specimens were considered to carry amplifica-
tion of the EGFR gene when .10% of the tumor cells exhibited
either an EGFR:CEP7 ratio .2 or multiple tight clusters of
hybridization signals for the EGFR gene probe. Homozygous
deletion was defined as $5% of tumor nuclei with centromeric
probe signals in the absence of signals for the locus specific probe.
Real Time RT-PCR validation of microarray-based mRNA
levels
Microarray mRNA expression levels of four relevant genes
(BCAS2, FIP1L1, EGFR, and XIST) coded in 4 different
chromosomes (chromosomes 1, 4, 7 and X) were validated by
an independent Quantitative Real-Time RT-PCR assay in a total
of 14 GBM samples (G8, G10, G14, G17, G30,G34, G37, G40,
G42, G44, G45, G46, G52 and G53). For this purpose the
SuperScript III first-strand Synthesis System from Invitrogen
(www.invitrogen.com) and both the LightCycler carousel-based
system and the LightCycler TaqMan Master chemistry (Ro-
che,Mannhein, Germany) were used, according to the instructions
of the manufacturers.
Statistical analyses
The statistical significance of differences observed between
groups was assessed by the Student T and the Mann-Whitney U
tests, for parametric and non-parametric (continuous) variables,
respectively; for qualitative variables, the X2 test was used (SPSS
software, SPSS 15.0, SPSS Inc, Chicago, IL, USA). Survival
curves were plotted according to the method of Kaplan and Meier,
and the log-rank test was used to assess the statistical significance
of differences in overall survival between groups of patients (SPSS
software). P-values,0.05 were considered to be associated with
statistical significance.
In order to investigate the impact of CN alterations on GEP, the
relationship between DNA CN values and GEP mRNA levels was
assessed for 12,445 genes investigated in common with both the
SNP-arrays and the GEP arrays, using the Pearson correlation
(Supplementary table S1). The correlation between real
Time RT-PCR and microarray-based mRNA levels of the
BCAS2, FIP1L1, EGFR, and XIST genes was assessed by the
Spearman correlation.
Results
Chromosomal localization of amplicons and
homozygous deletions
Overall, a higher number of amplicons than homozygous
deletions was observed with both the 6.0 and 500KSNP-arrays.
Recurrent amplicons were localized in chromosomes 7 (50% of the
cases), 12 (22%), 1 (11%), 4 (9%), 11 (4%), and 17 (4%); in turn,
homozygous deletions frequently involved chromosomes 9 (52%)
and 10 (22%) and less frequently, chromosomes 1, 6, 12, 13, 16
and 17 (one case each).
By far, chromosome 7p11.2 was the most frequently amplified
chromosomal region (n = 21/46 patients; 46%); two additional
cases showed amplicons at chromosome 7q (Figure 1 and
Supplementary Table S3). In turn, a high frequency of amplicons
was also noted in the long arm of chromosome 12 with recurrent
involvement of the 12q14.1 (8/46 cases; 17%), 12q13.3 (6/46
patients, also showing 12q14.1 amplicons; 13%) and 12q15 (4/46
patients, three of which also showed 12q14.1 amplicons; 9%)
cytobands; another four cytobands of chromosome 12 _12q13.12,
12q13.13, 12q14.3 and 12q21.1_ were affected in only one tumor
each. Other recurrent amplicons involved chromosomes 4q12 (4/
46 patients; 9%) and 1q32.1 (3/46 patients; 7%) (Figure 1 and
Supplementary Table S3). Four additional cytobands were
amplified in chromosomes 11 (11p13,11p15.3, 11q13.3 and
11q25), and 17 (17q25.1, 17q11.1, 17q11.2 and 17q24.1) in only
two tumors each (Supplementary Table S3).
In some patients, coexistence of two or three amplicons in
different chromosomes was observed. These included amplicons at
chromosomes 4, 7 and 12 in one case (case G82), at chromosome 7
and chromosome 12 in four patients (cases G39, G53, G70 and
G71), at chromosomes 4 and 12 in another two tumors (cases G82
and G88), at chromosomes 1 and 7 in two cases (cases G65 and
G83), at chromosomes 7 and 11 in one patient (G23) and at
chromosomes 7 and 17 in another case (G81) (Supplementary
Table S3). In other cases, amplicons were restricted to a single
chromosome: chromosome1 in one patient (case G79; 2%),
chromosome 4 in two tumors (G12 and G73; 4%), chromosome
12 in two cases (G46 and G51; 4%) and chromosome 7 in 11
patients (G30, G37, G40, G44, G55, G67, G68, G72, G80, G91
and G94; 24%).
Recurrent homozygous deletions were only found for chromo-
somes 9 (52%) and 10 (22%) (Figure 2 and Supplementary Table
S4). Despite homozygous deletion of chromosome 9 showed a
highly variable extension, it mainly involved chromosome 9p21.3
and less frequently, chromosome 9p21.2, 9p22.1 and 9p23
(Supplementary Table S4). Ten tumors (G10, G15, G42, G55,
G65, G67, G70, G72, G79 and G80) displayed homozygous
deletions of chromosome 10 at different regions: 10q23.31,
10q23.2, 10q21.3, 10q26.3, 10p13, 10q11.21, 10q22, 10q23.33
and 10q24.32 (Figure 2 and Supplementary Table S4); homozy-
gous deletions involving the 10q21.3 chromosomal region
occurred in only four tumors (G65, G72, G79 and G80), but
they frequently involved different loci; another 5 tumors (G10,
G42, G55, G67 and G70) showed homozygous losses at 10q23.2–
10q23.31 but, once again, they frequently involved distinct loci.
Other homozygous deletions were observed in a single tumor and
they involved chromosomes 13q14.2 and 12q24 (case G97),
Copy Number and Gene Expression in GBM
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16q22.1–16q23.2 and 1p36 (case G72), 17p12 (case G89) and
6q21 (case G80) (Supplementary Table S4).
iFISH analysis systematically confirmed the presence of the
above described amplicons and homozygously deleted chromo-
somal regions (Supplementary Table S2); although variable
patterns of numerical changes were revealed by iFISH at the
single cell level, in line with previous observations [31]; such
intratumoral iFISH heterogeneity was not detected by the SNP
CN profiles as exemplified in Supplementary Table S5 for
chromosomes 7 and 9.
Detailed characterization of the amplified and
homozygously deleted chromosomal segments
Characterization of the amplified chromosomal regions in GBM
revealed variable lengths for recurrent amplicons. Overall,
amplified segments in chromosome 7 ranged from 280 Mb to
5,681 Mb and those at chromosome 7p11.2 systematically
included the EGFR gene (n= 21 samples; 46%) frequently in
association with the LANCL2 (n = 12; 26%), VSTM2A (n = 8;17%)
and VOPP1(n = 7; 15%) genes (Figure 1 and Supplementary Table
S3).
Recurrently amplified segments for chromosome 12 ranged
from 44 Mb to 1,479 Mb and they included distinct segments
localized at 12q including up to 41 different genes (Supplementary
Table S3). Among other, these included the CYP27B1, METTL1,
FAM119B, TSFM and AVIL genes at chromosome 12q14.1 in 8/
46 patients (17%), and the CDK4 and AGAP2 genes in 7 GBM
(15%). In addition, amplification of the 12q13.3 chromosomal
region involved the GEFT and B4GALNT1 genes in 6 patients
(13%) and recurrent amplification of chromosome 12q15 involved
the MDM2 gene together with the SLC35E3 and CPM genes in 4
cases (9%).
For those four tumors with amplicons at chromosome 4q12
(G12, G73, G82 and G88), the PDGFRA, CHIC2, LNX1, FIP1L1,
and SCFD2 genes were found to be systematically amplified, the
length of the amplified chromosome 4q12 region varying between
1,022 Kb to 5,251 Kb (Figure 1).
The amplified chromosomal region at 1q32.1 (n = 3/46 tumors;
7%) showed a length of between 585 Kb and 864 Kb, and it
systematically included the MDM4 gene together with another
seven genes (SOX13, ETNK2, REN, KISS1, GOLT1A, PLEKHA6
and PIK3C2B (Figure 1 and Supplementary Table S3).
Figure 1. Frequently amplified chromosomal regions in GBM. Detailed characterization of the extension and the gene coded in those
segments of chromosomes 1 (A), 4 (B), 7 (C) and 12 (D) found to be recurrently amplified in GBM by SNP-arrays. The identification code for each
tumor isplaced on top of each line (G–N.), the length size of the amplicon in Kb is placed at the bottom of the amplified regions, and both the starting
and ending positions of the amplicons are shown at the left of each chromosomal region. All genes affected in common for each amplified
chromosomal segment are displayed; previously reported candidate genes amplified in a significant number of cases are shown in red, other
frequently amplified genes are depicted in blue, whereas genes depicted in black correspond to genes amplified at low frequencies. A total of 6
amplified genes (DCUN1D4, LRRC66*, SGCB, SPATA18, USP46, RASL11B) and fifteen amplicons (LOC644145*, EXOC1, CEP135, KIAA1211, AASDH, PPAT,
PAICS, SRP72, ARL9, GLDCP1*, HOPX, REST, C4orf14, POLR2B, IGFBP7) were additionally found in cases G12 and G73, respectively. Genes without
expression values in the GEP-array are highlighted with square boxes in the figure and with an asterisk in this legend.
doi:10.1371/journal.pone.0046088.g001
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Another 10 chromosomal regions from chromosomes 1, 11 and
17 were amplified in only one tumor each and they involved a
variable number of genes (between 1 and 37 genes) (Supplemen-
tary Table S3).
The most frequent homozygous deletion found involved
chromosome 9p21.3 from the 21,978,443 bp to the
22,119,128 bp position. This segment included the CDKN2A gene
in 24 patients (52%), together with the CDKN2B and CDKN2BAS
genes in 22 of them (48%). The MTAP (12 cases; 26%),
LOC554202 (8 tumors; 17%), ELAVL2 (5 GBM; 11%), and
TUSC1 (5 cases; 11%) genes were also frequently lost. Noteworthy,
in a subset of 7 of the former 24 cases, homozygous deletion of the
9p21.3 segment extended telomericly to the 21,186,931 bp
position including between three (n = 4 cases) and four (n = 3)
genes more (IFNA7, IFNA4 and IFNA17 without or with the
KLHL9 gene, respectively) (Figure 2 and Supplementary Table
S4). By contrast, the localization of the deleted regions in
chromosome 10 was highly heterogeneous extending from the
13,320,848 bp to the 134,174,753 bp positions, with an overall
length of between 4to 8,726 Mbp; among these cases, the PTEN
gene was homozygously deleted in 3 tumors (Figure 2 and
Supplementary Table S4). Another two genes _DNA2 and
SLC25A16 _were lost at the 10q21.3 region in another 3 cases,
and twenty genes coded at the 10q23.31 chromosomal region or
near it _the ATAD1, LIPK, LIPN, LIPM, ANKRD22, STAMBPL1,
ACTA2, FAS, FASAS, CH25H, LIPA, IFIT2, IFIT3, IFIT1B, IFIT1,
IFIT5, SLC16A12, PANK1, FLJ37201 and KIF20B genes_ were
homozygously lost in 2 other cases (Supplementary Table S4). Of
note, the RB1 tumor suppressor gene coded at chromosome
13q14.2 was homozygous deleted together with the RCBTB2 gene
in only one tumor (G97) from our series (Supplementary Table
S4).
Copy number alterations and gene expression levels
Out of 12,445 genes present in common in both the SNP and
GEP arrays (including 259/305 amplified or homozygously
deleted genes), 46 genes showed a high correlation (R2.0.70)
between DNA CN values and GEP RNA levels in paired GBM
tumor-PB samples (n = 23) (Table 2). Noteworthy, all except three
of these 46 genes were coded in those chromosomes carrying
amplicons: 10 in chromosome 1, 10 in chromosome 4, 4 in
chromosome 7, 1 in chromosome 11, 18 in chromosome 12. The
MTAP gene was the only gene coded in a homozygously deleted
chromosomal region (chromosome 9p21) for which a significant
Figure 2. Frequently homozygously deleted chromosomal regions in GBM. Recurrent homozygously deleted segments of chromosomes 9
(9p21.2 and 9p21.3) (A) and 10 (10p13, 10q11, 10q21, 10q22, 10q23, 10q24 and 10q26) (B). The identification code for each tumor is placed on top of
each line (G–N.), the length of the deleted chromosomal region in Kb is placed at the bottom of the lines corresponding to each deleted region, and
both the starting and ending positions of the deleted segments are shown at the left of each chromosomal region. All genes coded in each deleted
chromosomal region are displayed: previously reported candidate genes deleted in a significant number of cases are shown in red, other recurrently
deleted genes are depicted in blue, while genes deleted at low frequencies are shown in black.. Genes without expression values in the array are
highlighted with square boxes in the figure.
doi:10.1371/journal.pone.0046088.g002
Copy Number and Gene Expression in GBM
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e46088
correlation was found between CN alterations and gene expression
levels (Table 2). Of note, a high correlation was observed between
the microarray expression levels and quantitative RT-PCR
analysis of the mRNA levels of 4 selected relevant genes (BCAS2,
FIP1L1, EGFR and XIST) with Spearman correlation coefficients
of 0.6, 0.8, 0.8 and 0.9, respectively.
Those genes whose expression was mostly impacted by the most
frequent CN alterations were the RAP1B, TSFM, CYP27B1,
METTL1, AVIL, CDK4 and FAM119B genes in chromosome
12q14, the EGFR gene in chromosome 7p11 and the TMEM165,
FIP1L1, CLOCK, SRD5A3 and SCFD2 genes in chromosome 4q. As
mentioned above the MTAP gene was the only gene whose
expression was highly correlated to the occurrence of homozygous
deletion of chromosome 9p21.
From the prognostic point of view, none of the amplified and
homozygous deletions showed a clear impact on patient survival,
except for the amplification of the PDGFRA gene in chromosome
4q, which was associated with a significantly shorter overall
survival (median overall survival of 2 vs 13 months for the
PDGFRA amplified vs non-amplified cases ; p = 0.0002) (Figure 3).
Discussion
Identification of genetic markers involved in the oncogenic
mechanisms and molecular pathways driving GBM, still remains a
challenge. Among other approaches, detailed characterization of
amplicons and homozygous deletions provides a useful tool for the
screening and identification of candidate genes, despite pathogenic
mechanisms (e.g. gene mutation, epigenetic silencing through gene
methylation and altered expression microRNA) exist which are
not directly related to CN alterations. Several techniques have
been previously used for the identification of CN alterations in
GBM, including high-resolution SNP-arrays [23,32,33,34].
Through such approaches, CN gains of chromosome 7p11.2,
together with del(9p21) and monosomy 10/del(10q), have been
commonly observed in GBM, together with other less frequent
abnormalities [10,12,35]. Although the information from such
analyses is useful for the identification of both the altered
chromosomal regions and the genes they contain, valuable insights
into the role of relevant involved genes requires further assessment
of the impact of genomic aberrations on gene expression. In this
study, we integrated genomic and transcriptional data from paired
DNA and RNA samples from the same tumors, in order to identify
those genes involved in amplicons and homozygously deleted
chromosomal regions which show a parallel change in their
mRNA expression levels.
Analysis of whole-genome CN alterations by SNP-arrays
confirmed the presence of previously reported recurrent genomic
alterations in GBM [2,3,5], which were further validated here by
iFISH. Overall, almost every tumor in our cohort showed CN
alterations in multiple chromosomes, but their frequency and
extent varied significantly among different tumors, confirming the
genetic complexity of GBM [31]. Interestingly however, those
regions recurrently affected by CN alterations consistent with gene
amplification, were restricted to a few chromosomes (chromo-
somes 1q, 4q, 7p and 12q). Similarly, recurrent homozygous
deletions only involved chromosomes 9p21 and 10q23. Since
many genes involved in gliomagenesis often reside within
amplicons and/or homozygously deleted chromosomal regions,
we searched for candidate genes encoded in these regions for
which a correlation existed between the DNA CN values and
mRNA expression levels in the same tumor sample. Noteworthy,
virtually all genes which showed a high correlation (R2.0.70)
between DNA CN values and mRNA levels corresponded to genes
coded in those six chromosomes where amplicons were recurrently
observed. Amplified genes included several genes (MDM4,
PDGFRA, EGFR, CDK4, and MDM2) whose amplification has
been previously associated with the pathogenesis of GBM
[8,18,36,37]; in addition, other candidate genes were also found
to be amplified at both the DNA and RNA levels and thus, to be
potentially relevant in the pathogenesis of GBM.
In detail, the EGFR oncogene whose amplification defines a
subset of GBM [3,38,39], was the only gene coded in the 7p11.2
amplicon for which a significantly high correlation between DNA
CN values and gene expression levels was detected; although this
amplicon contained other bystander genes that may be co-
amplified with EGFR (e.g. LANCL2 and GASP) due to their
genomic proximity [14], amplification of all such genes showed
limited impact on gene expression levels. These results support
and reinforce the critical role of EGFR in the pathogenesis of a
significant fraction of GBM, through activation of the RAS
pathway [40,41].
Amplification of chromosome 12q13–15 was also found in a
significant proportion of primary GBM, in line with previous
reports [17]. In contrast to 7p11.2 amplicons, 12q13–15
amplicons typically involved multiple genes whose expression
was increased at the RNA level in parallel to the greater DNA CN
values.. However, from all these genes listed in table 2, only AVIL,
FAM119B, METTL1, CYP27B1 and TSFM were systematically
amplified in tumors displaying 12q amplicons..Co-amplification of
the CDK4 and MDM2 genes at the 12q13–15 amplicon is
frequently observed in GBM and it has been previously suggested
to confer a tumor growth advantage [42]. However, in our series
this amplicon showed no impact on the mRNA gene expression
levels of these two genes. By contrast, relatively little is known
about the role of other co-amplified and overexpressed genes
which are coded in chromosome 12q13–15, even if several of them
are also amplified in other tumors, e.g. in lung cancer [43]. From
these genes, special attention should be paid to the AVIL and
CYP27B1 genes. AVIL encodes for advillin, a member of the
gelsolin/villin family of actin regulatory proteins which is almost
exclusively expressed by peripheral sensory neurons, and that has
been recently identified as a new candidate driver gene in GBM
[44,45]. In turn, CYP27B1 (P450 Cytochrome 25-Hydroxyvita-
min D3 1,a-Hydroxylase) catalyzes the conversion of calcidiol to
calcitriol, the most active vitamin D metabolite, involved in cell
proliferation with both anti-proliferative and cell differentiating
effects [46,47,48]. Conversely, the role of FAM119B (a gene of
unknown function, which has been associated to multiple sclerosis)
[49], METLL1 _a nuclear protein that catalyzes the formation of
N(7)-methylguanine at position 46 (m7G46) in tRNA, inactivated
in response to agonists of the PI3-kinase pathway or the classical
MAP kinase cascade_, and TSFM (a gene that encodes the
mitochondrial translation elongation factor EFTs) in GBM,
deserves further investigations.
Amplification of chromosome 4q12 has been previously
described to involve the PDGFRA gene in 8–15% of GBM
[21,50], as also found here. However, CN alterations at 4q12 did
not show a high correlation with PDGFRA mRNA levels from the
same tumor. Conversely, expression of other amplified genes
coded at 4q12 in the vicinity of the PDGFRAgene (e.g. FIP1L1 and
SCFD2), appeared to be significantly modulated by the 4q12
amplicon, suggesting their potential relevance in GBM. In this
regard, it should be noted that the FIP1L1 protein coded by the
FIP1L1 gene functions as a component of the cleavage and
polyadenylation specificity factor (CPSF), which participates in
processing of mRNA. Although, it has been observed that fusion of
the FIP1L1 gene to the PDGFRA gene generated by interstitial
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Table 2. Relationship between the CN alterations and gene expression levels for 12,445 genes analyzed in parallel with the SNP
and GEP arrays, in GBM (n = 23).
Gene Name Symbol Cytoband R2
Cold shock domain containing E1, RNA-binding CSDE1 1p22 0.93
Transcription termination factor, RNA polymerase II TTF2 1p22 0.75
Breast carcinoma amplified sequence 2 BCAS2 1p21-p13.3 0.90
Amylase, alpha 2B (pancreatic) AMY2B 1p21 0.71
TryptophanyltRNA synthetase 2, mitochondrial WARS2 1p13.3-p13.1 0.85
Synaptotagmin VI SYT6 1p13.2 0.78
Mannosidase, alpha, class 1A, member 2 MAN1A2 1p13 0.89
Adenosine monophosphate deaminase 1 (isoform M) AMPD1 1p13 0.83
Immunoglobulin superfamily, member 3 IGSF3 1p13 0.76
Zinc fingerprotein 697 ZNF697 1p12 0.82
Signal recognition particle 72kDa SRP72 4q11 0.77
Transmembrane protein 165 TMEM165 4q12 0.92
FIP1 like 1 (S. cerevisiae) FIP1L1 4q12 0.92
Exocyst complex component 1 EXOC1 4q12 0.90
Clock homolog (mouse) CLOCK 4q12 0.88
Polymerase (RNA) II (DNA directed) polypeptide B POLR2B 4q12 0.87
Steroid 5 alpha-reductase 3 SRD5A3 4q12 0.77
DCN1, defective in cullin neddylation 1, domain containing 4 DCUN1D4 4q12 0.75
Chromosome 4 open reading frame 14 C4orf14 4q12 0.74
Sec1 family domain containing 2 SCFD2 4q12 0.71
Transmembrane protein 106B TMEM106B 7p21.3 0.84
Epidermal growth factor receptor EGFR 7p12 0.85
Peroxisome biogenesis factor 1 PEX1 7q21.2 0.79
GATA zinc finger domain containing 1 GATAD1 7q21–q22 0.78
Methylthioadenosine phosphorylase MTAP 9p21 0.73
Eukaryotic translation initiation factor 3, subunit M EIF3M 11p13 0.78
IMP1 inner mitochondrial membrane peptidase-like * IMMP1L 11p13 0.75
Amplified in osteosarcoma OS9 12q13 0.86
Methyltransferase like 1 METTL1 12q13 0.82
Solute carrier family 16, member 7 SLC16A7 12q13 0.78
Cytochrome P450, family 27, subfamily B, polypeptide 1 CYP27B1 12q13.1–q13.3 0.87
Phosphatidylinositol-5-phosphate 4-kinase, type II, gamma PIP4K2C 12q13.3 0.90
Deltex 3 homolog (Drosophila) DTX3 12q13.3 0.75
Beta-1,4-N-acetyl-galactosaminyl transferase 1 B4GALNT1 12q13.3 0.72
Methyl-CpG binding domain protein 6 MBD6 12q13.3 0.75
Tstranslation elongation factor, mitochondrial TSFM 12q13–q14 0.87
Carboxy-terminal domain small phosphatase 2 CTDSP2 12q13–q15 0.91
RAP1B, member of RAS oncogene family RAP1B 12q14 0.97
Cyclin-dependent kinase 4 CDK4 12q14 0.81
Family with sequence similarity 119, member B FAM119B 12q14.1 0.80
Advillin AVIL 12q14.1 0.78
Glutamate receptor interacting protein 1 GRIP1 12q14.3 0.95
Mdm2, transformed 3T3 cell double minute 2 MDM2 12q14.3–q15 0.96
Nucleo porin 107kDa NUP107 12q15 0.85
Solute carrier family 35, member E3 SLC35E3 12q15 0.79
X (inactive)-specific transcript * XIST Xq13.2 0.96
Only those genes (n = 46) which showed a high degree of correlation between CN alterations and RNA levels (R2.0.70; p-value,0.0000005) are shown.
*The IMMP1L (11p13) and the XIST (Xq13.2) genes were not amplified or deleted.
doi:10.1371/journal.pone.0046088.t002
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4q12 deletion, results in a constitutively activated FIP1L1-
PDGFRA fusion protein with tyrosine kinase activity in chronic
eosinophilic leukemiar [51] the role of the FIP1L1 gene in
gliomagenesis, remains to be dilucidated.
Other potentially relevant genes coded at chromosome 4q12
whose CN alterations mostly impacted on their mRNA expression
levels included the TMEM165 and the CLOCKgenes. TMEM165
(also named TPARL), encodes a putative transmembrane 324
amino acid protein whose cellular functions are unknown,
although intronic splice mutations of the protein have been
related to congenital disorders of glycosylation [52]. Of note,T-
MEM165 has been found to be up-regulated in invasive GBM cells
with transcriptional differences between these and the other core
tumor cells, supporting a role for this gene in tumor invasion [53].
In turn, theCLOCK protein contributes to activate transcription
of the Period (PER1, PER2, and PER3) and Cryptochrome
(CRY1 and CRY2) proteins two proteins that are involved in the
circadian system. Deregulation of the circadian clock protein has
been implicated in many types of cancer, in both animal and
humans [54,55,56,57]. In a recent study on gliomas including
GBM, tumor cell expression of PER1 and PER2 was significantly
lower than in the surrounding normal/reactive cells [58],
suggesting that deregulated expression of these two genes may
result in disruption of the control of the normal circadian rhythm
and a stimulatory effect on survival and proliferation of gliomas
cells. However, the molecular mechanisms of genes controlling
circadian rhythm in glioma cells have not been explored so far.
Independently of the precise impact of the molecular mechanisms
involved, amplification at the 4q12 chromosomal region was
associated with a very short patient overall survival.
Amplification of other chromosomal regions such as chromo-
some 1q32 was found in a relatively limited number of cases, in
line with previous findings [3,8,24]., Controversial results exist as
regards the impact of 1q32 amplicon on MDM4 and CNTN2, as
independent versus combined targets for amplification [20]. Our
results support an independent and more relevant role for the
Figure 3. Overall survival curves of GBM patients (n = 45) according to the presence vs absence of amplification of the PDGFRA
(Panel A), EGFR (Panel B) and MDM4 genes (Panel C) and the presence vs absence of deletion of the PTEN gene (Panel D).
doi:10.1371/journal.pone.0046088.g003
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former gene as the target of 1q32 amplification, since a higher
frequency of MDM4 amplification in the absence of involvement
of CNTN2 was observed in our patients; despite this, in our series,
7 other candidate genes were amplified together with MDM4.
These included the PIK3C2B gene involved in the PI3K/AKT
signaling pathway, which was also amplified and overexpressed in
other series of GBM [20], and the SOX13 gene, which has been
reported to be up-regulated in oligodendrogliomas [59]. Despite
this, none of the amplified genes at chromosome 1q32 was
associated with simultaneously increased RNA expression, further
investigations being required to confirm their relevance in the
pathogenesis of GBM.
Commonly deleted segments at chromosome 9p21, almost
systematically involve the CDKN2A tumor suppressor gene, in
association with both the CDKN2B gene, and frequently also the
MTAP gene [60,61,62,63,64], in line with our results. CDKN2A/B
gene products are involved in the p53 pathway through a
protein_p14arf_ encoded by an alternate reading frame, which
binds to the p53/mdm complex and inhibits mdm-mediated
degradation of p53. Thus, homozygous deletion of the CDKN2A/B
locus could affect both the Rb and p53 pathways [6,9].
Interestingly, it has been shown that MTAP can be lost
independently of CDKN2A, which suggests that loss of MTAP
may indeed play a role in tumor biology. Noteworthy, MTAP was
the single homozygously deleted gene at chromosome 9p21 for
which a high correlation was found between DNA CN values and
its mRNA expression levels. These results point out the potential
relevance of MTAP as a tumor suppressor gene. The MTAP
protein is an enzyme that plays a major role in polyamine
metabolism and that is essential for salvaging both adenine and
methionine. This enzyme is expressed in all normal human tissues,
but MTAP protein deficiency or MTAP gene deletion have been
previously found in several tumors, including gliomas [63]. This is
particularly relevant if we consider that the deleted segments at
9p21 encompassed, not only the CDKN2A/B tumor suppressor
genes, but also numerous other potentially relevant genes, such as
the ELAVL2 (its absence in Drosophyla causes multiple structural
defects and hypotrophy of the CNS), KLHL9 [encodes a substrate-
specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-
protein ligase complex, required for mitotic progression and
cytokinesis], and IFNA (IFNA7, IFNA4, and IFNA17) genes.
Monosomy 10 in association or not with del(10q) is a frequent
finding in GBM. Despite multiple chromosomal segments were
homozygously deleted in a small fraction of our cases, they rarely
involved the same chromosomal regions and none of the deleted
genes encoded in these areas, including the PTEN gene, showed a
high correlation between its DNA CN values and mRNA gene
expression levels.
In summary, here we confirm the high frequency of gene
amplification in GBM, which mainly involves the 7p11.2, 12q13–
15, and to a less extent also the 4q12 and 1q32 chromosomal
regions. Most interestingly, amplification of those genes coded in
these chromosomal segments showed a variable impact on their
mRNA levels, depending on the specifically targeted gene.
Conversely, recurrent homozygous deletions were restricted to
chromosome 9p21 and to multiple variable segments of chromo-
some 10q, the MTAP gene being the only gene whose mRNA
levels were significantly affected by such homozygous deletions.
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